Application of Bcl-2 (B cell lymphoma)/IgH (immunoglobulin H) gene rearrangement used as B cell lymphoma bone marrow infiltration marks

Abstract

The invention discloses an application of Bcl-2 (B cell lymphoma)/IgH (immunoglobulin H) gene rearrangement used as B cell lymphoma bone marrow infiltration marks. The application provided by the invention is particularly an application of substances and/or instruments for detecting Bcl-2 gene and IgH gene rearrangement to the preparation of products for screening B cell lymphoma suspected bone marrow infiltration or potential bone marrow infiltration patients, and B cell lymphoma is diffuse large B cell lymphoma (DLBCL). Experiments prove that compared with the traditional single bone marrow smear morphology dyeing method, the morphology method combined with FISH (Fluorescence In Situ Hybridization) method has the advantage that the positive rate (DLBCL is 33.0 percent and is 10.3 percent) is higher than that of the single morphology dyeing method. The bone marrow smear FISH is used for detecting Bcl-2/IgH gene rearrangement, in addition, the bone marrow infiltration of 83.3 percent of cases with 1 to 5 percent of naive lymphocyte in the bone marrow smear morphology can be more early diagnosed to different degrees than the single morphology dyeing method, and the early warning for at least more than three months is realized by compared with the clinical recurrence. Powerful supplementation is provided for the clinical analysis, the treatment and the reexamination after the cure of the lymphoma bone marrow infiltration.

Description

Technical field [0001] The present invention relates to the application of Bcl-2 / IgH gene rearrangement as a marker of B-cell lymphoma bone marrow infiltration, and particularly relates to substances used to detect Bcl-2 / IgH gene rearrangement or / and equipment for preparing and screening B-cell lymphoma Application of products for patients with suspected bone marrow infiltration or potential bone marrow infiltration. Background technique [0002] B-cell lymphoma (B-NHL) is one of the intractable diseases in the histopathological diagnosis of tumors. It has a wide variety and complicated classification. Diffuse large B-cell lymphoma (DLBCL) is the most frequent non-Hodgkin lymphoma (NHL) The type of hair, accounts for 30-40% of newly diagnosed NHL. [0003] Due to the histological characteristics of hematopoietic cells in the bone marrow, conventional pathological histomorphology and immunohistochemical staining techniques can detect bone marrow invasion, combined with leukemia sta...

AI Technical Summary

Problems solved by technology

[0003] Due to the histological characteristics of hematopoietic cells in the bone marrow, conventional pathological histomorphology and immunohistochemical staining techniques can detect bone marrow invasion, combined with leukemia stage, the microinfiltration of bone marrow can not meet the diagnostic needs, microinfiltration lesions are lymphoma recurrence The main root of DLBCL, whether bone marrow infiltration directly affects the stage of DLBCL, and then affects the treatment and prognosis

[0004] At present, the common method to evaluate the bone marrow infiltration of lymphoma is the morphological staining of bone marrow smear cells. Lead to false positives and false negatives; second, it is routinely judged that immature lymphocytes ≥ 5% are bone marrow invasion, while normal bone marrow immature lymphocytes ≤ 1%

This raises the following urgent question for us: For bone marrow morphology examination with immature lymphocytes between 1-5%, how to judge which ones are normal and which ones are potential microinfiltrations with negative bone marrow morphology? Bone marrow morphology examination is important, how to add other auxiliary means to reduce human factors and achieve standardization as much as possible? Individualized treatment requires the laboratory to propose an individualized diagnosis. How can bone marrow examination provide a valuable target for the next step of clinical targeted therapy? There are currently no satisfactory answers to these questions

Furthermore, it is currently known that some gene abnormalities and protein expression abnormalities do not appear simultaneously

Images